Johnson & Johnson MedTech has announced significant advancements in its treatment for atrial fibrillation (AF) through the presentation of new clinical and real-world data on its integrated VARIPULSETM Platform. This announcement comes ahead of the joint annual meeting of the Asia Pacific Heart Rhythm Society (APHRS) and the Japanese Heart Rhythm Society (JHRS), taking place from November 12-15, 2025, in Yokohama, Japan.
The VARIPULSETM Platform, which comprises the VARIPULSETM Catheter, TRUPULSETM Generator, and CARTOTM 3 Mapping System, has gained approval for use in multiple regions including the United States, Europe, Asia Pacific, Canada, and Latin America. To date, over 25,000 procedures have been successfully performed utilizing this technology across various countries, including Japan, Australia, and several nations in Europe and North America.
As part of its commitment to advancing patient care, Johnson & Johnson will showcase a series of key presentations and educational sessions during the conference. These will highlight improvements in safety, efficacy, and workflow related to pulsed field ablation (PFA) procedures.
Jing Li, Vice President of Electrophysiology & Neurovascular at Johnson & Johnson MedTech, emphasized the importance of the data being presented. “The clinical evidence we’re showcasing reflects our deep commitment and the comprehensive strength of our leading portfolio for atrial fibrillation and complex arrhythmias,” Li stated. This initiative is aimed at optimizing irrigation and supporting consistent procedural outcomes.
Several critical studies will be featured during the event. The QUEST AF study will present findings on the “Acute success of persistent atrial fibrillation ablation with a temperature-controlled very high-power short-duration radiofrequency catheter.” Another significant contribution will be from the VARIPURE (SECURE) study, which will provide insights into workflow efficiency and vein-level analysis for a novel pulsed field ablation variable loop circular catheter.
Additionally, the admIRE study will explore the impact of age and diagnosis-to-ablation time on sex differences in 12-month outcomes after catheter ablation for atrial fibrillation. Presentations will also address procedural characteristics associated with same-day discharge after pulsed field ablation treatment.
The REAL AF study will examine various outcomes related to ablation efficacy, including markers for successful atrial fibrillation treatment. The research aims to shed light on nuanced differences in outcomes based on patient characteristics, which could enhance future treatment protocols.
Johnson & Johnson MedTech is committed to expanding collaboration with the clinical community to gather further real-world evidence surrounding the VARIPULSETM Platform. This collaboration aims to accelerate patient-centered innovation in the treatment of atrial fibrillation.
The company continues to lead the way in addressing complex health challenges, particularly through its cardiovascular portfolio. This includes advanced mapping and navigation technologies as well as precise ablation techniques, focusing on conditions with significant unmet medical needs such as heart failure and coronary artery disease.
As Johnson & Johnson prepares to share its findings at APHRS and JHRS, the company reaffirms its dedication to improving patient outcomes and fostering scientific advancements in healthcare.
